{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:06:17Z","timestamp":1775257577766,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The pandemic outbreak of Coronavirus Disease 2019 (COVID-19) led to the development of mRNA vaccines. With the extensive vaccination campaign performed worldwide, many adverse reactions to these drugs have been reported in the literature. Although most of them are mild and self-limiting, they may sometimes cause psychological stress and require efforts to make a differential diagnosis with other conditions. This is the case of lymphadenopathies and lymphedema in patients with a history of cancer. Herein we present a case of lymphedema of the arm developed ten days after a VAXZEVRIA COVID-19 vaccine shot in a patient who had concomitant signs and symptoms compatible with a diagnosis of dermatomyositis. It was later classified as paraneoplastic as instrumental investigation revealed a breast carcinoma contralateral to the site of vaccine injection. With this report we ponder an adverse reaction to COVID-19 vaccination with the aim of bringing new data for clinicians who face similar clinical presentations, particularly controversial for radiologists and oncologists.<\/jats:p>","DOI":"10.3390\/vaccines10081219","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T23:49:27Z","timestamp":1659397767000},"page":"1219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lymphedema of the Arm after COVID-19 Vaccination in a Patient with Hidden Breast Cancer and Paraneoplastic Dermatomyositis"],"prefix":"10.3390","volume":"10","author":[{"given":"Cristina","family":"Aimo","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-1037","authenticated-orcid":false,"given":"Elena Biancamaria","family":"Mariotti","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-4998","authenticated-orcid":false,"given":"Alberto","family":"Corr\u00e0","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Quintarelli","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"},{"name":"Rare Diseases Unit, Azienda USL Toscana Centro, Section of Dermatology, Department of Health Sciences, University of Florence, European Reference Network Skin Member, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Verdelli","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"},{"name":"Rare Diseases Unit, Azienda USL Toscana Centro, Section of Dermatology, Department of Health Sciences, University of Florence, European Reference Network Skin Member, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0307-6636","authenticated-orcid":false,"given":"Valentina","family":"Ruffo di Calabria","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy"},{"name":"Rare Diseases Unit, Azienda USL Toscana Centro, Section of Dermatology, Department of Health Sciences, University of Florence, European Reference Network Skin Member, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"ref_1","unstructured":"(2022, July 18). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria-previously-covid-19-vaccine-astrazeneca."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apa.16172","article-title":"Multisystem inflammatory syndrome and COVID-19 vaccine","volume":"111","author":"Sookaromdee","year":"2022","journal-title":"Acta Paediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.arcmed.2020.04.016","article-title":"Ongoing challenges faced in the global control of COVID-19 pandemic","volume":"51","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.puhe.2021.01.009","article-title":"COVID-19 vaccine dilemmas","volume":"202","author":"Lee","year":"2022","journal-title":"Public Health"},{"key":"ref_5","first-page":"13524585221109397","article-title":"A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database","volume":"13","author":"Kim","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104022","DOI":"10.1016\/j.msard.2022.104022","article-title":"Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis","volume":"65","author":"Stennett","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lupica, A., Di Stefano, V., Iacono, S., Pignolo, A., Quartana, M., Gagliardo, A., Fierro, B., and Brighina, F. (2022). Impact of COVID-19 in AChR Myasthenia Gravis and the safety of vaccines: Data from an italian cohort. Neurol. Int., 27.","DOI":"10.3390\/neurolint14020033"},{"key":"ref_8","first-page":"e1","article-title":"American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 2","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","first-page":"11829","article-title":"Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: Can therapy affect the immunological response?","volume":"288","author":"Benucci","year":"2022","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1055\/s-0042-1745788","article-title":"Coronavirus disease 2019 vaccination for cancer patients: Risk or benefit?","volume":"44","author":"Laporte","year":"2022","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4161\/hv.24657","article-title":"Vaccine hesitancy: An overview","volume":"9","author":"Laberge","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","first-page":"2021-12-3","article-title":"Addressing COVID-19 vaccine hesitancy","volume":"20","author":"Kassianos","year":"2022","journal-title":"Drugs Context"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.acra.2021.04.007","article-title":"Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review","volume":"28","author":"Keshavarz","year":"2021","journal-title":"Acad. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/RLU.0b013e3182177322","article-title":"In-cidence and intensity of F-18 FDG uptake after vaccination withH1N1 vaccine","volume":"36","author":"Burger","year":"2011","journal-title":"Clin. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorn\u00e1, A., Attia, S., Klugarov\u00e1, J., Ko\u0161\u010d\u00edk, M., and Klugar, M. (2021). Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech republic. J. Clin. Med., 1.","DOI":"10.3390\/jcm10071428"},{"key":"ref_17","first-page":"e13524","article-title":"Lymphadenopathy associated with the COVID-19 vaccine","volume":"23","author":"Hiller","year":"2021","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1097\/MD.0000000000028092","article-title":"Transient lower extremity lymphedema following COVID-19 vaccination: A case report","volume":"100","author":"Chung","year":"2021","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-021-05314-2","article-title":"Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: Incidence assessed by [18F] FDG PET-CT and relevance to study interpretation","volume":"48","author":"Cohen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/000155502753600894","article-title":"Dermatomyositis in 132 patients with different clinical subtypes: Cutaneous signs, constitutional symptoms and circulating antibodies","volume":"82","author":"Parodi","year":"2002","journal-title":"Acta Derm. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jid.2018.08.017","article-title":"Advances in cutaneous lupus erythematosus and dermatomyositis: A report from the 4th international conference on cutaneous lupus erythematosus-an ongoing need for international consensus and collaborations","volume":"139","author":"Concha","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_23","first-page":"2329","article-title":"Dermatomyositis associated with breast cancer","volume":"26","author":"Pectasides","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: An update for the clinician","volume":"175","author":"Sieb","year":"2022","journal-title":"Clin Exp. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study","volume":"6","author":"Stockton","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.55563\/clinexprheumatol\/vskjxi","article-title":"Idiopathic inflammatory myopathies: One year in review 2021","volume":"40","author":"Cardelli","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1111\/jdv.18060","article-title":"Two cases of anti-TIF1-\u03b3 antibody positive dermatomyositis with manifested symptoms after SARS-CoV-19 vaccination","volume":"36","author":"Yoshida","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","first-page":"4","article-title":"Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination","volume":"27","author":"Kreuter","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.autrev.2013.08.005","article-title":"A review on the association between inflammatory myopathies and vaccination","volume":"13","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2216172","DOI":"10.1001\/jamanetworkopen.2022.16172","article-title":"Frequency and outcomes of ipsilateral axillary lymphadenopathy after COVID-19 vaccination","volume":"5","author":"Zhou","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.seminoncol.2021.10.002","article-title":"COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature","volume":"48","author":"Lim","year":"2021","journal-title":"Semin Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"875637","DOI":"10.3389\/fimmu.2022.875637","article-title":"Misdiagnosis of reactive lymphadenopathy remotely after COVID-19 vaccination: A case report and literature review","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Akiyama, T., Ueda, N., Matsumura, S., Mori, M., Namiki, M., Yamada, N., Tsutsumi, C., Tozaki, S., and Iwamoto, H. (2022). COVID-19 Vaccination in patients with cancer. Cancers, 14.","DOI":"10.21203\/rs.3.rs-1352502\/v1"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2967\/jnumed.121.262194","article-title":"COVID-19 mRNA Vaccination: Age and immune status and its association with axillary lymph node PET\/CT uptake","volume":"63","author":"Eifer","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_35","first-page":"uxac065","article-title":"Immune cell-antibody interactions in health and disease","volume":"26","author":"Karagiannis","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jmv.27599","article-title":"Lymphadenopathy post-COVID-19 vaccination with increased FDG uptake may be falsely attributed to oncological disorders: A systematic review","volume":"94","author":"Bshesh","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.15557\/JoU.2021.0060","article-title":"Axillary adenopathy after COVID-19 vaccine in patients undergoing breast ultrasound","volume":"21","author":"Giorgis","year":"2021","journal-title":"J. Ultrason."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2214\/AJR.21.25728","article-title":"COVID-19 Vaccination-Related Uptake on FDG PET\/CT: An emerging dilemma and suggestions for management","volume":"217","author":"McIntosh","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_39","first-page":"20210040","article-title":"COVID-19 vaccine-related lymph node activation\u2014Patterns of uptake on PET-CT","volume":"7","author":"Shah","year":"2021","journal-title":"BJR Case Rep."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:59:41Z","timestamp":1760140781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081219"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081219","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}